Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0598934 (
tumor growth
)
58,965
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recent studies have reported that microRNA-526b (miR-526b) is implicated in the growth and metastasis of cancer cells. However, the clinical significance of miR-526b and its role as well as underlying mechanisms are largely unknown in hepatocellular carcinoma (HCC). Here, we detected miR-526b expression difference between HCC and matched nontumor tissues with qRT-PCR. We found that miR-526b displayed lower expression in HCC patient tissues and cells. Clinical analysis revealed that low miR-526b expression correlated with large tumor size, venous infiltration, advanced tumor-node-metastasis (TNM) stage. Furthermore, miR-526b underexpression independently predicted poor prognosis of HCC patients. Functionally, we demonstrated that miR-526b inhibited proliferation, migration and invasion of HCC cells
in vitro
. Moreover, miR-526b overexpression restrained the
tumor growth
and pulmonary metastasis
in vivo
. Mechanistically, we proved that miR-526b could directly bind to 3'UTR of
sirtuin 7
(
SIRT7
) mRNA and repressed its expression. miR-526b and
SIRT7
showed a negative correlation in HCC tissues. More importantly, up-regulating
SIRT7
expression antagonized miR-526b-inhibited proliferation, migration and invasion in SMMC-7721 cells. Furthermore, miR-526b suppressed epithelial-to-mesenchymal transition (EMT) of HCC cells. Immunoblotting analysis indicated that miR-526b reduced the levels of phosphorylated ERK (p-ERK), c-Myc, Cyclin D1, c-Jun, SNAIL and SLUG in HCC cells.
SIRT7
restoration promoted phosphorylation of ERK and EMT in miR-526b overexpressing SMMC-7721 cells. Taken together, this is the first time we demonstrated that miR-526b might function as a prognostic biomarker and suppressed
SIRT7
expression, and subsequently led to the growth and metastasis of HCC. Our findings provide miR-526b/
SIRT7
axis as a promising drug target for HCC.
...
PMID:microRNA-526b servers as a prognostic factor and exhibits tumor suppressive property by targeting Sirtuin 7 in hepatocellular carcinoma. 2915 16
There is growing evidence that microRNA-148b (miR-148b) can inhibit the growth of malignant cells while
sirtuin 7
(
SIRT7
) may perform its carcinogenic effect by deacetylating H3K18. This study investigated the mechanism of miR-148b/
SIRT7
on how it affects the malignant biological behavior of melanoma. It was established that the expression of miR-148b was downregulated in melanoma while that of
SIRT7
was upregulated but negatively regulated by miR-148b through binding to the 3'UTR of
SIRT7
. Ectopic expression of miR-148b reduced the proliferation, migration, and invasion of melanoma cells, but
SIRT7
reversed these functions of miR-148b. Moreover,
tumor growth
and metastasis experiments showed that miR-148b could significantly suppress proliferation and metastasis of melanoma
in vivo
. Overall, miR-148b inhibits the malignant biological behavior of melanoma by reducing the expression level of
SIRT7
. The development of miR-148b as a novel potential therapeutic approach for melanoma may be possible in the future.
...
PMID:MicroRNA-148b Inhibits the Malignant Biological Behavior of Melanoma by Reducing Sirtuin 7 Expression Levels. 3327 32